TWI657818B - 用於治療細菌感染的方法 - Google Patents

用於治療細菌感染的方法 Download PDF

Info

Publication number
TWI657818B
TWI657818B TW104117219A TW104117219A TWI657818B TW I657818 B TWI657818 B TW I657818B TW 104117219 A TW104117219 A TW 104117219A TW 104117219 A TW104117219 A TW 104117219A TW I657818 B TWI657818 B TW I657818B
Authority
TW
Taiwan
Prior art keywords
mycoplasma
mic
human
compound
bacterial
Prior art date
Application number
TW104117219A
Other languages
English (en)
Chinese (zh)
Other versions
TW201607537A (zh
Inventor
麥可 修班德
Original Assignee
英商安特西醫療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商安特西醫療有限公司 filed Critical 英商安特西醫療有限公司
Publication of TW201607537A publication Critical patent/TW201607537A/zh
Application granted granted Critical
Publication of TWI657818B publication Critical patent/TWI657818B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW104117219A 2014-05-29 2015-05-28 用於治療細菌感染的方法 TWI657818B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
US62/004,246 2014-05-29

Publications (2)

Publication Number Publication Date
TW201607537A TW201607537A (zh) 2016-03-01
TWI657818B true TWI657818B (zh) 2019-05-01

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104117219A TWI657818B (zh) 2014-05-29 2015-05-28 用於治療細菌感染的方法

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
EA033459B1 (ru) 2019-10-31
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
MX365261B (es) 2019-05-27
PH12016502271B1 (en) 2017-02-06
KR20170007818A (ko) 2017-01-20
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
AU2015265620B2 (en) 2020-04-09
SG11201609404SA (en) 2016-12-29
CN106659725A (zh) 2017-05-10
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Spížek et al. Lincomycin, clindamycin and their applications
US10039777B2 (en) Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
Bekő et al. Antibiotic susceptibility profiles of Mycoplasma hyorhinis strains isolated from swine in Hungary
TWI657818B (zh) 用於治療細菌感染的方法
CN103565798A (zh) 广藿香酮及其衍生物的新用途
Ramasamy et al. Molecular characterization of antibiotic resistance gene pattern of Staphylococcus aureus and Escherichia coli in mastitis affected dairy cows.
Azimirad et al. Infection with enterotoxigenic Staphylococcus aureus as a concern in patients with gastroenteritis
Langbang et al. A study on bacterial pathogens causing secondary infections in patients suffering from tuberculosis and their pattern of antibiotic sensitivity
RU2388827C1 (ru) Способ определения чувствительности микроорганизмов с множественной лекарственной устойчивостью к сочетаниям антибактериальных препаратов
Abdu et al. Prevalence of qnr genes among multidrug resistance Staphylococcus aureus from clinical isolates
Ayeni Prevalence, diagnosis and local susceptibility of staphylococci infections
US12534766B2 (en) Rapid detection of antimicrobial resistance by microbial ribosome immunoprecipitation
US20070281992A1 (en) Combination of gyrase b inhibitors and protein synthesis inhibitors and uses thereof
Ali et al. Antimicrobial Susceptibility Pattern of Staphylococcus Species from Clinical Sample
Rouev et al. Analysis of nasal and pharyngeal microbiological isolates collected in 2023 in Hospital Trakia–Stara Zagora
Abass et al. Phenotypic and Genotypic Study of Biofilm Formation of Multi-Drug Resistant Staphylococcus aureus Isolated from Different Clinical Infections/Iraq
Kulaste et al. Prevalence of microorganisms causing mastitis in dairy animals and their antibiotic resistance
Khalid et al. Nasal colonization and antimicrobial susceptibility pattern of Staphylococcus species among children in Lahore, Pakistan
Khan et al. Prevalence of multidrug resistant Staphylococcus aureus isolates in clinical specimens collected from local patients of Chittagong, Bangladesh
Soleimani et al. The effect of zinc nanoparticles inhibitor of efflux pumps NorA and NorB in clinical isolated of Staphylococcus aureus from skin infections. Med Biomedical Journal. 1 (1). 40-52
Bowman et al. Antimicrobial effects of isolated prodigiosin from Serratia marcescens in comparison to antibiotics
CN116139131A (zh) 酚妥拉明增强红霉素对鲍曼不动杆菌的抗菌活性的应用
Bagde et al. Study of antibiotic susceptibility test of modern generation of drugs against upper respiratory tract pathogens
Ovesen Choice of antimicrobial treatment for anaerobic infections with Bacteroides spp. in horses
JP2013515727A (ja) 抗菌剤としてのキブデロスポランギウム（ｋｉｂｄｅｌｏｓｐｏｒａｎｇｉｕｍ）由来抽出物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees